The client needed to evaluate the commercial potential of a compound in Phase III clinical trials. The compound will most likely be reserved for second-line therapy for target patients due to potential side effects and dosing administration.

A competitor had launched in the same class that was first to market; thus, it was important to understand the level of product differentiation based on available safety, efficacy, and administration data.

Further, emerging data on sequential therapy with other classes of drugs suggested that new treatment paradigms may affect the commercial potential of the product.

The client engaged MattsonJack's assistance in developing a detailed forecast to help assess the commercial potential of the compound.

MattsonJack captured the perspectives of physicians, payers and patients through primary market research designed to:

• identify which patient segments offer key opportunities
• determine anticipated usage patterns including sequential use of other classes of drugs
• understand compliance issues considering the high cost of the product and relatively benign nature of disease before fracture
• assess price sensitivity and determine the expected formulary status
  
• assess the impact of a potential risk (black box scenarios)
  

MattsonJack used assumptions developed from the primary market research as the foundation of its forecast.